TBIQYR5139-Global Atropine Market Research Report 2019

                                          
Atropine is a medication to treat certain types of nerve agent and pesticide poisonings as well as some types of slow heart rate and to decrease saliva production during surgery. It is typically given intravenously or by injection into a muscle. Eye drops are also available which are used to treat uveitis and early amblyopia. The intravenous solution usually begins working within a minute and lasts half an hour to an hour. Large doses may be required to treat some poisonings.
Atropine is a medication to treat certain types of nerve agent and pesticide poisonings as well as some types of slow heart rate and to decrease saliva production during surgery. It is typically given intravenously or by injection into a muscle. Eye drops are also available which are used to treat uveitis and early amblyopia. The intravenous solution usually begins working within a minute and lasts half an hour to an hour. Large doses may be required to treat some poisonings.

Atropine industry is relatively fragmented, manufacturers are mostly in the North America, Europe and Asia, and China market production volume accounted for more than 25.43% of the total production volume of global Atropine in 2017. C²PHARMA is the world leading manufacturer in global Atropine market with the market share of 9.19%, in terms of revenue, followed by RESONANCE LABORATORIES, ROLABO OUTSOURCING, Minsheng Group and CR Double-Crane.

Compared to 2016, Atropine market decreased revenue by 5.69 percent to $549.60 million worldwide in 2017 from $582.76 million in 2016. As for the volume segment, global Atropine production decreased to 3862.8 Kg from 4247.4 Kg in 2013. Due to low prices, small profit margins and a relatively narrow market, many companies have abandoned production of atropine, and a shortage of atropine has appeared in the market. This is the result of long-term effects of market behavior.

The average price of Atropine will fall further. The product average price declined in the past few years due to its cheap drug properties, and the average price will keep this trend in the few future years due to market vicious circle. 


The global Atropine market is valued at 550 million US$ in 2018 is expected to reach 480 million US$ by the end of 2025, growing at a CAGR of -1.7% during 2019-2025.
This report focuses on Atropine volume and value at global level, regional level and company level. From a global perspective, this report represents overall Atropine market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    C²PHARMA
    RESONANCE LABORATORIES
    ROLABO OUTSOURCING
    Minsheng Group
    CR Double-Crane
    HENAN PURUI
    Albany Molecular Research
    Alchem International
    SAURAV CHEMICALS
    Katsura Chemical
    Hangzhou Vega
    Wuhan senwayer century

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    Injection
    Drop
    Gel

Segment by Application
    Gastrointestinal
    Ophthalmology
    Other